article thumbnail

FDA approves Coherus’ Cimerli for DME, with year-long interchangeability exclusivity

Pharmaceutical Technology

In addition, for doctors who do use Lucentis, there will be added pressure from payers to switch to Cimerli with its direct interchangeability with Lucentis approved. The post FDA approves Coherus’ Cimerli for DME, with year-long interchangeability exclusivity appeared first on Pharmaceutical Technology.

article thumbnail

Elucirem (gadopiclenol) is FDA-Approved for Contrast-Enhanced MRI

XTalks

Guerbet, a pharmaceutical company based in France that specializes in medical imaging, obtained US Food and Drug Administration (FDA) approval for Elucirem (gadopiclenol), a new macrocyclic GBCA. XTALKS WEBINAR: Response Prediction in Oncology Clinical Trials. Clinical Trials of Elucirem.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves AbbVie’s Vuity as the First Eyedrop for Presbyopia

XTalks

We are proud to offer Vuity as a first-of-its-kind once-daily eye drop that we believe will change the way people and their eye doctors approach presbyopia. The FDA approval of Vuity exemplifies our continued pursuit of innovative new treatments that push the boundaries of what’s possible in eye care.”.

article thumbnail

FDA grants approval for Amylyx’s Relyvrio to treat ALS

Pharmaceutical Technology

The FDA approval is based on findings from the multicentre Phase II CENTAUR clinical trial that enrolled 137 ALS patients. For the first three weeks, the recommended dose is one packet a day. Following this time period, the dosage is raised to one packet twice daily.

article thumbnail

Understanding FDA’s Draft Guidance on Ethical Considerations for Involving Children in Clinical Trials

Advarra

In 2016, the Food and Drug Administration (FDA) approved Spinraza (nusinersen). While the FDA’s approval of nusinersen may not seem extraordinary, it was. Nusinersen’s approval marked the first time nonclinical data supported conducting initial clinical trials involving children.

article thumbnail

Omlonti Granted FDA Approval in Glaucoma and Ocular Hypertension

XTalks

Register for this free webinar to learn how dry eye disease ophthalmic trials are embracing new technologies to accelerate programs and gain better insights into product efficacy. Omlonti Reduces Intraocular Pressure and is Well-Tolerated in Clinical Trials. in the press release.

article thumbnail

FDA Approves J&J’s Darzalex Faspro for Rare Light Chain Amyloidosis

The Pharma Data

Food and Drug Administration (FDA) approved Janssen Pharmaceuticals ’ (a Johnson and Johnson company) Darzalex Faspro for adults with newly diagnosed light chain amyloidosis. It was approved in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd). Michael Vi/Shutterstock. It was developed with Genmab.